We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock

Delisted

DCPH was delisted on the 10th of June, 2024.

88 hedge funds and large institutions have $822M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 35 increasing their positions, 22 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 22

3% more capital invested

Capital invested by funds: $795M → $822M (+$27.2M)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

6% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 16

1% less funds holding

Funds holding: 8988 (-1)

Holders
88
Holders Change
-1
Holders Change %
-1.12%
% of All Funds
2.01%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
15
Increased
35
Reduced
22
Closed
16
Calls
$352K
Puts
Net Calls
+$352K
Net Calls Change
+$352K
Name Holding Trade Value Shares
Change
Change in
Stake
NLVP
1
New Leaf Venture Partners
New York
$159M
O
2
OrbiMed
New York
$75.6M -$1.93M -52,200 -3%
SHI
3
SV Health Investors
Massachusetts
$66.5M
RG
4
Redmile Group
California
$57.2M -$18.5K -500 -0%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$36.4M -$8.99M -243,205 -21%
PC
6
Polar Capital
United Kingdom
$31.2M +$7.78M +210,453 +35%
Viking Global Investors
7
Viking Global Investors
Connecticut
$28.5M -$24.5M -662,893 -47%
EA
8
Emerald Advisers
Pennsylvania
$27.3M +$4.15M +112,290 +19%
Janus Henderson Group
9
Janus Henderson Group
United Kingdom
$26.3M +$4.46M +120,683 +22%
BlackRock
10
BlackRock
New York
$26.2M +$3.13M +84,754 +14%
Vanguard Group
11
Vanguard Group
Pennsylvania
$26.2M +$520K +14,081 +2%
EMFAT
12
Emerald Mutual Fund Advisers Trust
Pennsylvania
$25.8M +$5.73M +155,082 +30%
State Street
13
State Street
Massachusetts
$22.7M +$16.2M +438,630 +298%
AllianceBernstein
14
AllianceBernstein
Tennessee
$22.6M +$4.02M +108,871 +23%
Norges Bank
15
Norges Bank
Norway
$19.4M
OM
16
Opaleye Management
Massachusetts
$16.3M
Alkeon Capital Management
17
Alkeon Capital Management
New York
$14.5M +$13.9M +375,000 New
Lord, Abbett & Co
18
Lord, Abbett & Co
New Jersey
$14M +$127K +3,439 +1%
ACH
19
ArrowMark Colorado Holdings
Colorado
$12.8M +$613K +16,593 +5%
Citadel Advisors
20
Citadel Advisors
Florida
$12.2M +$10.6M +287,991 +1,048%
DCM
21
Driehaus Capital Management
Illinois
$9.41M +$285K +7,715 +3%
VC
22
Vivo Capital
California
$8.23M -$1.49M -40,294 -16%
KCM
23
Kornitzer Capital Management
Kansas
$7.29M
Deutsche Bank
24
Deutsche Bank
Germany
$5.53M +$1.01M +27,232 +24%
Alyeska Investment Group
25
Alyeska Investment Group
Illinois
$5.48M

DCPH Hedge Fund Activity: Q3 2018 in Review

88 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q3 2018, worth a combined $822M — up 3.4% from $795M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of DCPH and 15 opened new positions — a net loss of 1 holder — while 22 trimmed existing stakes and 35 added.

The largest buyer was State Street, adding an estimated $16.2M. The largest seller was Viking Global Investors, cutting an estimated $24.5M.

  • 88 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q3 2018, down from 89 in Q2 2018.
  • Funds reported $822M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q3 2018, up 3.4% quarter-over-quarter.
  • 15 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q3 2018 and 16 closed out, a net change of -1 holder.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q3 2018 was State Street, an estimated $16.2M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q3 2018 was Viking Global Investors, an estimated $24.5M sold.

Based on aggregated 13F filings for Q3 2018.